Clinical Cancer Research Grants Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, X.
Right arrow Articles by Cao, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, X.
Right arrow Articles by Cao, X.
Clinical Cancer Research Vol. 11, 7545-7553, October 15, 2005
© 2005 American Association for Cancer Research


Cancer Therapy: Preclinical

Silencing of Human Phosphatidylethanolamine-Binding Protein 4 Sensitizes Breast Cancer Cells to Tumor Necrosis Factor-{alpha}–Induced Apoptosis and Cell Growth Arrest

Xiaojian Wang1, Nan Li2, Hongzhe Li1, Bin Liu2, Jianming Qiu1, Taoyong Chen2 and Xuetao Cao1,2

Authors' Affiliations: 1 Institute of Immunology, Zhejiang University, Hangzhou, PR China and 2 Institute of Immunology, Second Military Medical University, Shanghai, PR China

Requests for reprints: Xuetao Cao, Institute of Immunology, Zhejiang University, 353 Yanan Road, Hangzhou 310031, Zhejiang, PR China. Phone: 86-21-2507-0316; Fax: 86-571-8721-7329; E-mail: caoxt{at}public3.sta.net.cn.

Purpose: The current therapeutic approach is not so effective in breast cancer patients. Alternative treatment protocols aimed at different targets need to be explored. We recently reported a novel phosphatidylethanolamine-binding protein, human phosphatidylethanolamine-binding protein 4 (hPEBP4), as an antiapoptotic molecule. The finding led us to explore a promising approach for breast cancer therapy via silencing the expression of hPEBP4.

Experimental Design: hPEBP4 expression in clinical breast specimens was examined by Tissue Microarrays. RNA interference was used to silence hPEBP4 expression in MCF-7 breast carcinoma cells and the effects on cell proliferation, cell cycle progression, apoptosis, as well as underlying mechanisms, were investigated.

Results: hPEBP4 was found to be expressed in up to 50% of breast cancers but in only <4% of normal breast tissues. Silencing of hPEBP4 potentiated tumor necrosis factor-{alpha} (TNF-{alpha})–induced apoptosis and cell cycle arrest in MCF-7 cells, which was due to the increased mitogen-activated protein kinase activation and the enhanced phosphatidylethanolamine externalization. Further investigation showed that silencing of hPEBP4 in MCF-7 cells promoted TNF-{alpha}-induced stability of p53, up-regulation of phospho-p53ser15, p21waf/cip, and Bax, and down-regulation of Bcl-2 and Bcl-xL, which were shown to depend on extracellular signal-regulated kinase 1/2 and c-jun NH2-terminal kinase activation by hPEBP4 silencing. Moreover, the increased proportion of cells in the G0-G1 phase of cell cycle was observed in hPEBP4-silenced MCF-7 cells on TNF-{alpha} treatment and the expression of cyclin A and cyclin E was down-regulated more significantly.

Conclusions: The antiapoptotic effect and the preferential expression pattern in breast cancer tissues make hPEBP4 a new target for breast cancer therapy. Silencing of hPEBP4 expression may be a promising approach for the treatment of breast carcinoma.




This article has been cited by other articles:


Home page
J. Immunol.Home page
Y. Zhang, Q. Liu, M. Zhang, Y. Yu, X. Liu, and X. Cao
Fas Signal Promotes Lung Cancer Growth by Recruiting Myeloid-Derived Suppressor Cells via Cancer Cell-Derived PGE2
J. Immunol., March 15, 2009; 182(6): 3801 - 3808.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Wang, B. Liu, N. Li, H. Li, J. Qiu, Y. Zhang, and X. Cao
IPP5, a Novel Protein Inhibitor of Protein Phosphatase 1, Promotes G1/S Progression in a Thr-40-dependent Manner
J. Biol. Chem., May 2, 2008; 283(18): 12076 - 12084.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Wang, N. Li, X. Liu, Y. Zheng, and X. Cao
A Novel Endogenous Human CaMKII Inhibitory Protein Suppresses Tumor Growth by Inducing Cell Cycle Arrest via p27 Stabilization
J. Biol. Chem., April 25, 2008; 283(17): 11565 - 11574.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Li, X. Wang, N. Li, J. Qiu, Y. Zhang, and X. Cao
hPEBP4 Resists TRAIL-induced Apoptosis of Human Prostate Cancer Cells by Activating Akt and Deactivating ERK1/2 Pathways
J. Biol. Chem., February 16, 2007; 282(7): 4943 - 4950.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Gonzalez-Gronow, M. Cuchacovich, C. Llanos, C. Urzua, G. Gawdi, and S. V. Pizzo
Prostate Cancer Cell Proliferation In vitro Is Modulated by Antibodies against Glucose-Regulated Protein 78 Isolated from Patient Serum
Cancer Res., December 1, 2006; 66(23): 11424 - 11431.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.